Works by Bikorimana, Emmanuel


Results: 11
    1
    2
    3
    4
    5
    6
    7

    PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.

    Published in:
    Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-46495-2
    By:
    • Lin, Chang-Ching;
    • Chang, Tsung-Cheng;
    • Wang, Yunguan;
    • Guo, Lei;
    • Gao, Yunpeng;
    • Bikorimana, Emmanuel;
    • Lemoff, Andrew;
    • Fang, Yisheng V.;
    • Zhang, He;
    • Zhang, Yanfeng;
    • Ye, Dan;
    • Soria-Bretones, Isabel;
    • Servetto, Alberto;
    • Lee, Kyung-min;
    • Luo, Xuemei;
    • Otto, Joseph J.;
    • Akamatsu, Hiroaki;
    • Napolitano, Fabiana;
    • Mani, Ram;
    • Cescon, David W.
    Publication type:
    Article
    8
    9
    10
    11